NCT02191540

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Abnoba Korea · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion

Conditions

• Malignant Pleural Effusion

Interventions

Type	Name	Description
DRUG	Abnoba Viscum F 20mg	intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space

Timeline

• Start date: 2011-01-01
• Primary completion: 2013-01-01
• Completion: 2013-05-01
• First posted: 2014-07-16
• Last updated: 2014-07-23

Locations

3 sites across 1 country: South Korea